-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SkYvySBL09gyjxQD7b5msmwnat41mGpVFPG6Q3zMSy4vDcFYwYYuXlEyDD08pxzE 5fRd33Gm6ojPhyX+spuA6w== 0000000000-06-046178.txt : 20061220 0000000000-06-046178.hdr.sgml : 20061220 20060925100423 ACCESSION NUMBER: 0000000000-06-046178 CONFORMED SUBMISSION TYPE: UPLOAD PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060925 FILED FOR: COMPANY DATA: COMPANY CONFORMED NAME: MEDTRONIC INC CENTRAL INDEX KEY: 0000064670 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 410793183 STATE OF INCORPORATION: MN FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: UPLOAD BUSINESS ADDRESS: STREET 1: 710 MEDTRONIC PKWY STREET 2: MS LC300 CITY: MINNEAPOLIS STATE: MN ZIP: 55432 BUSINESS PHONE: 7635144000 MAIL ADDRESS: STREET 1: 710 MEDTRONIC PKWY CITY: MINNEAPOLIS STATE: MN ZIP: 55432 PUBLIC REFERENCE ACCESSION NUMBER: 0000897101-05-001490 LETTER 1 filename1.txt August 23, 2006 Via U.S. Mail and Facsimile Arthur D. Collins, Jr. Chairman of the Board and Chief Executive Officer Medtronic, Inc. 710 Medtronic Parkway Minneapolis, Minnesota 55432 Re: Medtronic, Inc. Form 10-K for the Fiscal Year Ended April 28, 2006 Filed June 28, 2006 File No. 1-07707 Dear Mr. Collins: We have limited our review of your Form 10-K for the fiscal year ended April 28, 2006 to disclosure relating to your contacts with countries that have been identified as state sponsors of terrorism, and we have the following comments. Our review with respect to this issue does not preclude further review by the Assistant Director group with respect to other issues. At this juncture, we are asking you to provide us with supplemental information, so that we may better understand your disclosure. Please be as detailed as necessary in your response. After reviewing this information, we may raise additional comments. Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filings. We look forward to working with you in these respects. We welcome any questions you may have about our comments or on any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter. General 1. We note from your corporate website that you operate in the Middle East through a network of distributors, and that the countries you cover in that region include Iran, Sudan, and Syria. Iran, Sudan, and Syria are identified as state sponsors of terrorism by the State Department and are subject to U.S. economic sanctions. Your Form 10- K does not contain any information regarding your operations in or other contacts with these countries. Please describe to us in reasonable detail your past, current, and anticipated operations in and other contacts with each named country, whether through subsidiaries, affiliates, or other direct or indirect arrangements. Discuss specifically the extent to which you sell or distribute into these countries products medical or other equipment or devices, technology, or services. Describe the distribution arrangements, and any marketing or professional support activities, associated with these countries. Discuss any dealings with the governments of these countries, or with entities controlled by or affiliated with those governments. 2. Please discuss the materiality of the operations or other contacts described in response to the foregoing comment, and whether those operations or contacts, individually or in the aggregate, constitute a material investment risk for your security holders. You should address materiality in quantitative terms, including the dollar amounts of any associated revenues, assets, and liabilities. Please also address materiality in terms of qualitative factors that a reasonable investor would deem important in making an investment decision, including the potential impact of corporate activities upon a company`s reputation and share value. We note, for example, that Arizona and Louisiana have adopted legislation requiring their state retirement systems to prepare reports regarding state pension fund assets invested in, and/or permitting divestment of state pension fund assets from, companies that do business with countries identified as state sponsors of terrorism. The Pennsylvania legislature has adopted a resolution directing its Legislative Budget and Finance Committee to report annually to the General Assembly regarding state funds invested in companies that have ties to terrorist-sponsoring countries. The Missouri Investment Trust has established an equity fund for the investment of certain state-held monies that screens out stocks of companies that do business with U.S.-designated state sponsors of terrorism. Florida mandates issuers to disclose in their prospectuses any business contacts with Cuba or persons located in Cuba. Illinois, Oregon, Maine and New Jersey have adopted, and other states are considering, legislation prohibiting the investment of certain state assets in, and/or requiring the divestment of certain state assets from, companies that do business with Sudan. Harvard University, Stanford University, the University of California, and other academic institutions have adopted policies prohibiting investment in, and/or requiring divestment from, companies that do business with Sudan. Your materiality analysis should address the potential impact of the investor sentiment evidenced by such actions directed toward companies having operations in, or other business contacts with, Iran, Sudan, and Syria. 3. A public media report dated April 1, 2000 indicates that you attended a trade show in Cuba, a country identified as a state sponsor of terrorism by the State Department and subject to asset and export controls. To the extent that you have or anticipate any contacts with Cuba, or have had such contacts since the date of the trade show, please provide the same type of information regarding those contacts as is requested in comments 1-2. * * * * * Please respond to this comment within 10 business days or tell us when you will provide us with a response. Please file your response letter on EDGAR. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include all information required under the Exchange Act of 1934 and that they have provided all information investors require for an informed investment decision. Since the company and its management are in possession of all facts relating to the company`s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. In connection with responding to our comment, please provide, in writing, a statement from the company acknowledging that: * the company is responsible for the adequacy and accuracy of the disclosure in the filings; * staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filings; and * the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in our review of your filings or in response to our comments on your filings. Please understand that we may have additional comments after we review your response to our comment. Please contact Pradip Bhaumik, Attorney-Advisor, at (202) 551-3333 if you have any questions about the comments or our review. You may also contact me at (202) 551- 3470. Sincerely, Cecilia D. Blye, Chief Office of Global Security Risk cc: Angela Crane Accounting Branch Chief Division of Corporation Finance Neil Ayotte, Esq. Medtronic, Inc. Fax: (763) 505-2980 Arthur D. Collins, Jr. Medtronic, Inc. August 23, 2006 Page 1 -----END PRIVACY-ENHANCED MESSAGE-----